ANEBULO Pharmaceuticals Shares Surge 76.5% on Positive Phase 2 Trial Results
By ATTN Desk · Editorial oversight: Sean Han
Introduction
ANEBULO PHARMACEUTICALS INC (NASDAQ: ANEB) is a clinical-stage biotechnology company headquartered in Austin, Texas, specializing in the development of treatments for acute cannabinoid toxicity. As of July 23, 2025, its shares closed at $3.23, reflecting a 76.50% gain on trading volume of 4,595,542 shares. ANEBULO’s lead candidate, ANEB-001, is designed as a competitive CB1 receptor antagonist to address acute cannabinoid intoxication, a condition for which there is currently no approved antidote.
Corporate Structure
Founded in Texas, ANEBULO operates with a workforce of 11–50 employees in pharmaceutical manufacturing and research. The company is publicly traded on the NASDAQ under the ticker symbol ANEB. Investor relations are managed from its office located at 1017 Ranch Road 620 South, Suite 107, Lakeway, TX 78734, and Continental Stock Transfer & Trust Company serves as its transfer agent.
Cannabinoid Antagonist by vadim kaipov
Recent Developments
On July 23, 2025, ANEBULO’s share price increased to $3.23 from the previous close of $1.83, following the completion of Phase 2 proof-of-concept studies for ANEB-001. These studies indicated tolerability and efficacy in rapidly reversing THC effects in a controlled human challenge. The next earnings release is scheduled for September 23, 2025 (estimated). Additionally, ANEBULO is engaged in preclinical research to develop further formulations of its active pharmaceutical ingredient to broaden its product offerings for acute cannabinoid toxicities.
Financial and Strategic Analysis
ANEBULO’s market capitalization is approximately $75.2 million, with 41.08 million shares outstanding. To date, the company has reported no product revenue, reflective of its clinical-stage status. Key financial metrics (TTM) include:
| Metric | Value |
|---|---|
| Market Cap | $75.2 M |
| Shares Outstanding | 41.08 M |
| EPS | –$0.27 |
| P/E (TTM) | –6.84 |
| Fwd P/E (NTM) | 4.02 |
| EBITDA | –$8.233 M |
The company does not currently provide dividends and has a beta of –0.97. Its 52-week trading range spans from $0.80 (December 20, 2024) to $3.08 (September 20, 2024). Following the Phase 2 data release, ANEBULO intends to progress ANEB-001 into pivotal trials, aligning its capital allocation with regulatory milestones.
Market Position and Industry Context
Between 2012 and 2018, cannabis-related emergency room visits in the U.S. increased at a compound annual growth rate (CAGR) of 15% due to expanding legalization efforts. Although these visits plateaued during the COVID-19 pandemic, ongoing changes in legislation are projected to contribute to further increases. A physician survey indicated a need for a cannabinoid antagonist, scoring 7.52 out of 10. ANEBULO’s ANEB-001, as a small-molecule CB1 receptor antagonist, aims to fulfill this clinical need and could be positioned to become the first approved treatment for acute cannabinoid intoxication, pending successful Phase 3 trial outcomes.
TL;DR
- On July 23, 2025, ANEBULO shares rose 76.50% to $3.23 on a volume of 4.6 million.
- Phase 2 proof-of-concept data for ANEB-001 demonstrated effective reversal of THC effects with acceptable tolerability.
- The next financial report is estimated for September 23, 2025.
- ANEBULO is preparing to initiate Phase 3 trials based on Phase 2 outcomes, targeting regulatory approval for the first antidote for cannabinoid intoxication.